Description of Medical Service177Lutetium(nca) Octreotate is a radiopharmaceutical administered by infusion to patients with progressive or symptomatic Neuroendocrine Tumours (NET) if molecular imaging techniques demonstrate much higher levels of somatostatin receptors on the majority tumours sites compared to normal tissues. The initial treatment cycle most commonly comprises 4-5 infusions, given 6-8 weeks apart, and responding patients may be re-treated multiple times if symptoms recur or further tumour progression occurs.
Description of Medical ConditionNeuroendocrine tumours arise in a range of tissues from cells that function to regulate bodily function by secreting bioactive compounds, particularly peptide hormones. These tumours can be slowly or aggressively growing with excessive hormone secretion often adversely affecting the patient’s quality of life in lower-grade tumours, while high-grade tumours cause compromise of organ function and tissue integrity leading to premature death.
Reason for ApplicationNew MBS item
Medical Service TypeTherapeutic
Previous Application Number/sNot Applicable
Application FormApplication Form (PDF 1675 KB)
Application Form (Word 1001 KB)
Consultation SurveyConsultation Survey (PDF 653 KB)
Consultation Survey (Word 27 KB)
PASC consultation closes 7 July 2023
MSAC consultation TBA – please subscribe to the MSAC email bulletin to be notified when consultation opens for this application.
For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process
Public Summary Document-
Meetings for this Application
PASC13-14 April 2023
10-11 August 2023